Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis reports good Q1 performance

Sanofi-aventis has announced adjusted earnings per share were up 9.8 per cent at constant exchange rates for the first quarter of 2009

Sanofi-aventis has announced adjusted earnings per share (EPS) were up 9.8 per cent at constant exchange rates for the first quarter of 2009.

Consolidated net income was €1,578m, up on the €1,325m figure for the same period of 2008.

Sales growth was driven by strong performances from the company's flagship products, Lantus (up 27.1 per cent), Taxotere (up 8.3 per cent), Aprovel (up 11.1 per cent), and from vaccines (up 9.1 per cent). There was also strong growth in Plavix worldwide (up 8.6 per cent). 

Sales were up 5.1 per cent in the US, 8 per cent in emerging markets and 13.8 per cent in Japan. 

The company cited continuing tight control over industrial and operating costs as one of the reasons for the good figures, and said cash flow for the quarter had been sufficient to fund the acquisition of Zentiva and reduce net debt from €1.8bn to €1.2bn. 

The US Food and Drug Administration advisory committee's recommendation for approval of Multaq for atrial fibrillation in March had further boosted the results. 

Sanofi-aventis also highlighted significant gains in its generics business, with 2008 proforma net sales of approximately €1.2bn due to the acquisitions of Zentiva, Medley and Kendrick. It has refocused its R&D portfolio to concentrate on the most promising projects and accelerated external R&D alliances. Acquisition of BiPar Sciences strengthened its oncology R&D portfolio with the addition of the PARP inhibitor BSI-201.

Sanofi-aventis confirmed its expectations for growth in 2009 adjusted EPS excluding selected items of at least 7 per cent at constant exchange rates, barring major adverse events.

29th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics